TRVI Stock: Price, Earnings History and SEC Filings
Trevi Therapeutics, Inc. (TRVI) last traded at $13.56, down 1.81% on the latest session and down 5.3% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.11 against an analyst estimate of $-0.11, a beat of 0.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
TRVI earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.11 | $-0.11 | +0.00% |
| Mar 2026 | May 5, 2026 | $-0.09 | $-0.07 | -28.57% |
| Dec 2025 | Mar 17, 2026 | $-0.06 | $-0.10 | +40.00% |
| Sep 2025 | Nov 13, 2025 | $-0.08 | $-0.10 | +20.00% |
TRVI beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How TRVI reacts to earnings
Across its last 8 earnings releases, TRVI moved 2.3% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | After close | +0.05% |
| 2026-05-05 | After close | -2.73% |
| 2026-04-17 | Before open | +4.75% |
| 2026-03-17 | After close | -4.47% |
| 2025-11-13 | After close | -0.79% |
| 2025-08-07 | After close | +1.64% |
| 2025-05-08 | After close | +0.00% |
| 2025-03-18 | After close | +3.81% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
TRVI financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | – | -$43M | -$42M | – | $-0.32 |
| 2024 | – | -$48M | -$38M | – | $-0.47 |
| 2023 | – | -$29M | -$32M | – | $-0.29 |
| 2022 | – | -$29M | -$28M | – | $-0.45 |
| 2021 | – | -$34M | – | – | $-1.49 |
| 2020 | – | -$33M | -$29M | – | – |
| 2019 | – | -$26M | -$23M | – | – |
| 2018 | – | -$21M | -$18M | – | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for TRVI
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 4, 2026Bylaw change, Shareholder vote, Financial statements and exhibits
- 10-Q · May 5, 2026
- 8-K · May 5, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 21, 2026
- 424B5 · Apr 17, 2026
- 8-K · Apr 17, 2026Material agreement, Results of operations, Other events
- 424B5 · Apr 16, 2026
- 10-K · Mar 17, 2026
Insider filing activity
TRVI insiders filed 1 Form 4 report in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
TRVI news
- Trevi Therapeutics (TRVI) Stock May Still Look Expensive Against Book ValueNov 1, 2026 · finance.yahoo.com
- Trevi Therapeutics to Participate in Stifel's 2026 Healthcare ConferenceOct 27, 2026 · finance.yahoo.com
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. (TRVI) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.